8 results about "Normal blood glucose" patented technology

The invention discloses a glucose responsive composite material as well as a preparation method and application thereof. The composite material sequentially comprises porous metal, a polydopamine layer and a mesoporous silicon dioxide coating from inside to outside, the porous metal is coated with the polydopamine layer, the polydopamine layer is coated with the mesoporous silicon dioxide coating, and preparation raw materials of the mesoporous silicon dioxide coating comprise aminated mesoporous silicon dioxide, aspirin, 4-carboxyphenylboronic acid and sodium alginate. The composite material disclosed by the invention has blood sugar concentration dual-mode response capability, aspirin is suddenly released in a hyperglycemia environment, up-regulation expression of anti-inflammatory factors is remarkably promoted, and an anti-inflammatory effect is dominated; in a normal blood glucose environment, aspirin is slowly released, and the expression of osteogenic factors is remarkably up-regulated, so that osteogenic differentiation is promoted as a leading effect; the dual-mode response realizes accurate regulation and control of ASP dosage, organically combines bone formation promotion and anti-inflammatory functions, and provides a brand new solution for patients with bone defects, especially patients with bone defects caused by diabetes mellitus.

The invention relates to a preparation method and application of sugar-responsive protamine insulin, which comprises the following steps: modifying a chemical group on cysteine of protamine, connecting with a phenylboronic acid compound to form a compound, and mixing with insulin to prepare the sugar-responsive protamine insulin. The sugar-responsive insulin preparation can realize an intelligent sugar-responsive regulation mechanism. Specifically, the insulin can be slowly released at a normal blood glucose level and is accelerated to be released at a hyperglycemia state, so that the blood glucose is effectively regulated and controlled, and the occurrence of hypoglycemia is avoided.

The invention discloses a blood glucose monitoring whole-process management and control system for gestational diabetes patients, relates to the technical field of blood glucose supervision, and is characterized in that the gestational diabetes patients are subjected to continuous subcutaneous insulin infusion treatment and continuous glucose monitoring to obtain respective patient dynamic associated treatment data; a transmission path network is constructed for transmitting all the patient dynamic association treatment data, multi-factor data analysis is performed on the patient dynamic association treatment data, gestational diabetes patients at abnormal and normal blood glucose levels are monitored respectively, corresponding decision operations are decided according to different blood glucose levels and executed, and the gestational diabetes treatment data are obtained. The method comprises the following steps: establishing a respective data board of each gestational diabetes patient, executing respective blood glucose level data management through the data boards, establishing a follow-up visit window, performing whole-course follow-up visit on each gestational diabetes patient through the follow-up visit window, and performing personalized management and control on the gestational diabetes patients with substandard follow-up visit.

The application relates to the fields of Internet of Things and biomedical sensing technology, and discloses a non-invasive blood glucose concentration detection method based on passive UHF RFID, which comprises the following steps: fixing a passive UHF RFID tag on a preset monitoring part of the body surface of a living experimental animal, and placing the living experimental animal in a wireless signal reading area constructed by an RFID reader and an antenna thereof; and performing exogenous blood glucose regulation on the living experimental animal to make the blood glucose concentration in the living experimental animal produce dynamic changes covering the normal blood glucose concentration range. By constructing a standardized and systematic blood glucose detection process, from the early preparation of the experimental animal, exogenous blood glucose regulation, to the synchronous collection of signals and blood glucose reference values, and then to the preprocessing of the data set and the establishment of a quantitative model, each step is closely connected and the operation is standardized, random interference in the living experiment is effectively inhibited, and the reliability and stability of the detection data are guaranteed.

The present disclosure discloses a data acquisition and analysis method based on diabetes data analysis and processing equipment, and relates to the field of diabetes data analysis and prediction. The equipment includes a computer, a placement rack and a flow cytometer. The mitochondrial membrane potential data in the neutrophil is performed independent evaluation and analysis. If the proportion of cells with increased mitochondrial membrane potential are in the neutrophil is greater than 70%, the person is at the risk of diabetes, otherwise the risk is lower, so that the subsequent development of diabetes in a person with normal blood glucose can be predicted, and the diabetes can be prevented in advance.

This invention relates to a method for preparing glucose-responsive protamine insulin and its application. The method involves modifying chemical groups on the cysteine ​​residues of protamine and linking them with phenylboronic acid compounds to form a complex, which is then mixed with insulin to prepare glucose-responsive protamine insulin. This glucose-responsive insulin formulation achieves an intelligent glucose response regulation mechanism. Specifically, under normal blood glucose levels, the insulin is released slowly, while under hyperglycemic conditions, its release is accelerated, thereby achieving effective blood glucose control and preventing hypoglycemia.

Disclosed herein are compositions and uses for healthy weight management by providing a consumable composition comprising N-trans-caffeoyltyramine and N-transferuloyltyramine. Some embodiments provide for glucose management in a subject. Some embodiments provided include, for example, the consumable composition capable of supporting abdominal fat loss, visceral fat loss, maintaining lean body mass, and supporting normal blood glucose regulation.

The application discloses a blood glucose evaluation method, a user interface and related devices. The method can acquire a PPG signal of a user, and then display a blood glucose result of the user evaluated based on the PPG signal. The blood glucose result indicates a stage of the user in development from normal blood glucose to diabetes. It can be seen that the method takes into account that there is a development stage before normal blood glucose turns into diabetes, thereby achieving more refined evaluation of the blood glucose condition of the user, so that the user can have more refined management of the blood glucose of the user.